Hector G. Palmer

Hector G. Palmer

Auto-generated profile, based on publicly available information

Hector G. Palmer

Vall d’Hebrón Institut d’Oncología (VHIO), Stem Cell and Cancer Laboratory, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2017 in Nature Reviews Cancer
Verified
Journal Article
Open access
PDF file
ABAnnette T Byrne
Annette T Byrne
DADenis G. Alférez
Denis G. Alférez
FAFrédéric Amant
Frédéric Amant
DADaniela Annibali
Daniela Annibali
Joaquín ArribasJoaquín Arribas
Joaquín Arribas
LTLivio Trusolino
Livio Trusolino
Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.

20 May 2012 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
STStephan P Tenbaum
Stephan P Tenbaum
POPaloma Ordóñez-Morán
Paloma Ordóñez-Morán
IPIsabel Puig
Isabel Puig
ICIrene Chicote
Irene Chicote
OAOriol Arqués
Oriol Arqués
HPHéctor G Palmer
Héctor G Palmer

1 April 2003 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
JPJose Piedra
Jose Piedra
SMSusana Miravet
Susana Miravet
JCJulio Castaño
Julio Castaño
HPHéctor G. Pálmer
Héctor G. Pálmer
NHNora Heisterkamp
Nora Heisterkamp
MDMireia Duñach
Mireia Duñach
Read the full review for this F1000Prime recommended article: p120 Catenin-associated Fer and Fyn tyrosine kinases regulate beta-catenin Tyr-142 phosphorylation and beta-catenin-alpha-catenin Interaction.

22 August 2004 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
HPHéctor G Pálmer
Héctor G Pálmer
MLMaría Jesús Larriba
María Jesús Larriba
JGJosé Miguel García
José Miguel García
POPaloma Ordóñez-Morán
Paloma Ordóñez-Morán
CPCristina Peña
Cristina Peña
AMAlberto Muñoz
Alberto Muñoz

14 February 2018 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ASAnita Sveen
Anita Sveen
JBJarle Bruun
Jarle Bruun
PEPeter W. Eide
Peter W. Eide
IEIna A. Eilertsen
Ina A. Eilertsen
LRLorena Ramirez
Lorena Ramirez
RLRagnhild A. Lothe
Ragnhild A. Lothe
Purpose: Response to standard oncologic treatment is limited in colorectal cancer. The gene expression–based consensus molecular subtypes (CMS) provide a new paradigm for stratified treatment and drug repurposing; however, drug discovery is currently limited by the lack of translation of CMS to preclinical models. Experimental Design: We analyzed CMS in primary colorectal cancers, cell lines, and patient-derived xenografts (PDX). For classification of preclinical models, we developed an optimized classifier enriched for cancer cell–intrinsic gene expression signals, and performed high-throughput in vitro drug screening (n = 459 drugs) to analyze subtype-specific drug sensitivities. Results: The distinct molecular and clinicopathologic characteristics of each CMS group were validated in a single-hospital series of 409 primary colorectal cancers. The new, cancer cell–adapted classifier was found to perform well in primary tumors, and applied to a panel of 148 cell lines and 32 PDXs, these colorectal cancer models were shown to recapitulate the biology of the CMS groups. Drug screening of 33 cell lines demonstrated subtype-dependent response profiles, confirming strong response to EGFR and HER2 inhibitors in the CMS2 epithelial/canonical group, and revealing strong sensitivity to HSP90 inhibitors in cells with the CMS1 microsatellite instability/immune and CMS4 mesenchymal phenotypes. This association was validated in vitro in additional CMS-predicted cell lines. Combination treatment with 5-fluorouracil and luminespib showed potential to alleviate chemoresistance in a CMS4 PDX model, an effect not seen in a chemosensitive CMS2 PDX model. Conclusions: We provide translation of CMS classification to preclinical models and uncover a potential for targeted treatment repurposing in the chemoresistant CMS4 group. Clin Cancer Res; 24(4); 794–806. ©2017 AACR.

31 January 2016 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
OAOriol Arqués
Oriol Arqués
ICIrene Chicote
Irene Chicote
IPIsabel Puig
Isabel Puig
STStephan Paul Tenbaum
Stephan Paul Tenbaum
GAGuillem Argilés
Guillem Argilés
HPHéctor G. Palmer
Héctor G. Palmer
Purpose: Oncogenic mutations in the KRAS/PI3K/AKT pathway are one of the most frequent alterations in cancer. Although PI3K or AKT inhibitors show promising results in clinical trials, drug resistance frequently emerges. We previously revealed Wnt/β-catenin signaling hyperactivation as responsible for such resistance in colorectal cancer. Here we investigate Wnt-mediated resistance in patients treated with PI3K or AKT inhibitors in clinical trials and evaluate the efficacy of a new Wnt/tankyrase inhibitor, NVP-TNKS656, to overcome such resistance. Experimental Design: Colorectal cancer patient-derived sphere cultures and mouse tumor xenografts were treated with NVP-TNKS656, in combination with PI3K or AKT inhibitors.We analyzed progression-free survival of patients treated with different PI3K/AKT/mTOR inhibitors in correlation with Wnt/β-catenin pathway activation, oncogenic mutations, clinicopathological traits, and gene expression patterns in 40 colorectal cancer baseline tumors. Results: Combination with NVP-TNKS656 promoted apoptosis in PI3K or AKT inhibitor-resistant cells with high nuclear β-catenin content. High FOXO3A activity conferred sensitivity to NVP-TNKS656 treatment. Thirteen of 40 patients presented high nuclear β-catenin content and progressed earlier upon PI3K/AKT/mTOR inhibition. Nuclear β-catenin levels predicted drug response, whereas clinicopathologic traits, gene expression profiles, or frequent mutations (KRAS, TP53, or PIK3CA) did not. Conclusions: High nuclear β-catenin content independently predicts resistance to PI3K and AKT inhibitors. Combined treatment with a Wnt/tankyrase inhibitor reduces nuclear β-catenin, reverts such resistance, and represses tumor growth. FOXO3A content and activity predicts response to Wnt/β-catenin inhibition and together with β-catenin may be predictive biomarkers of drug response providing a rationale to stratify colorectal cancer patients to be treated with PI3K/AKT/mTOR and Wnt/β-catenin inhibitors. Clin Cancer Res; 22(3); 644–56. ©2015 AACR.